Wisp Launches GLP-1s Through New Weight Care Vertical

What You Should Know: 

–  Wisp, a women’s telehealth platform in the U.S., is significantly expanding its services to include weight management and enhanced menopause care. 

– Wisp’s expansion into weight management and enhanced menopause offerings reflect its commitment to providing comprehensive care for women at all stages of life. The company plans to further expand its services with more at-home diagnostics and treatment options in the future.

Addressing Weight Management Needs

Recognizing the impact of hormonal imbalances on weight, Wisp now offers personalized weight care consultations and a range of products to support women struggling with conditions like perimenopause, menopause, PCOS, and endometriosis. The platform provides access to:

  • Prescription GLP-1 Medications: Semaglutide (brand name Wegovy) and compounded semaglutide injections, including a sublingual option.
  • Over-the-Counter Supplements: Wisp’s exclusive Metabolic Support & GLP-1 Boost capsules, formulated with ingredients like Eriomin, Actiz!ng, Glucovantage, and PoZibio to support metabolic health.

Expanding Menopause Care

Wisp is also enhancing its menopause care offerings with new treatment options, including:

  • Prescription Estriol Face Cream: To address skin changes associated with menopause.
  • Hormone Replacement Therapy (HRT): Transdermal estradiol patches, oral micronized progesterone capsules, and oral Provera tablets.

Convenient and Accessible Care

Wisp’s telehealth platform provides convenient and accessible care for women across the U.S. Patients can request consultations and receive personalized treatment plans from the comfort of their homes. Medications and supplements can be obtained through pharmacy pickup or discreet home delivery.

“Wisp is committed to providing sustainable support for women’s weight loss journeys, addressing a critical yet overlooked aspect of women’s health,” said Monica Cepak, CEO of Wisp. “As the dialogue around obesity evolves, we recognize that underlying conditions — especially hormonal imbalances linked to perimenopause and menopause — remain under-researched, underdiagnosed, and undertreated. With these new offerings, we’re proud to continue expanding access to comprehensive care, offering tailored solutions for every woman and every condition at every price point.”